Predict your next investment

Corporation
HEALTHCARE | Drug Manufacturing / Generics
shinpoong.co.kr

See what CB Insights has to offer

Investments

2

About Shin Poong Pharm

Shin Poong Pharm (KRX: 019170) is a pharmaceutical company that specializes in manufacturing generics, therapeutics, anti-malarial treatments, and more.

Shin Poong Pharm Headquarter Location

161, Yeoksam-ro, Gangnam-gu

Seoul, 06246,

South Korea

+82-2-2189-3400

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Shin Poong Pharm Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Shin Poong Pharm Rank

Latest Shin Poong Pharm News

Osteoporosis Pipeline Review, H2 2020 - Therapeutics Development & Assessment, Drug Profiles, Dormant Projects, Product Milestones, Competitive Landscape - ResearchAndMarkets.com

Dec 11, 2020

Osteoporosis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 9, 8, 22, 4, 64, 15 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 14 and 14 molecules, respectively. Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Scope The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders). The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders) Reasons to Buy Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders). Classify potential new clients or partners in the target demographic. Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Key Topics Covered: Osteoporosis - Drug Profiles Dongkook Pharmaceutical Co Ltd Jiangsu T-mab BioPharma Co Ltd Keros Therapeutics Inc Nanomedic Inc Reliance Life Sciences Pvt Ltd Reven Pharmaceuticals Inc Shanghai Biomabs Pharmaceuticals Co Ltd Shanghai Celgen Bio-Pharmaceutical Co Ltd Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Shanghai Junshi Bioscience Co Ltd Shenzhen Salubris Pharmaceuticals Co Ltd Shin Poong Pharm Co Ltd Stelis Biopharma Pvt Ltd Tritech Biopharmaceuticals Co Ltd

Shin Poong Pharm Investments

2 Investments

Shin Poong Pharm has made 2 investments. Their latest investment was in C-BIOMEX as part of their Seed - III on December 12, 2018.

CBI Logo

Shin Poong Pharm Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/1/2018

Seed - III

C-BIOMEX

No

1

12/7/2017

Seed

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/1/2018

12/7/2017

Round

Seed - III

Seed

Company

C-BIOMEX

Subscribe to see more

Amount

$99M

New?

No

Subscribe to see more

Co-Investors

Sources

1

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.